Allan Eisemann, MD

Biography

Publications:

Eisemann A, Becker NJ, Miner PB Jr., Fleming J.  Pancreatitis and gold treatment of rheumatoid arthritis. Ann Int Med 1989; 111:860-61

Eisemann A, Ahn JA, Graziani G, Tronick SR, Ron D.  Alternative splicing generates at least five different isoforms of the human basic-FGF receptor.  Oncogene 1991; 6:1195-1202

Clinical Protocols:

Rutland Regional Medical Center as Supplemental Investigator

• A Phase III, randomized clinical trial of standard adjuvant endocrine therapy +/- chemotherapy in patients with 1-3 positive nodes, hormone receptor-positive and HER-2 negative breast cancer with recurrence score of 25 or less (SWOG S1007) 
• A randomized Phase III trial of adjuvant therapy comparing chemotherapy alone to chemotherapy plus trastuzumab in women with node-positive or high risk node-negative HER2-low invasive breast cancer (NSABP B-47) 
• A study of neratinib plus capecitabine versus lapatinib plus capecitabine in patients with HER-positive metastatic breast cancer who have received two or more HER-directed regimens in the metastatic setting (NALA Study, Puma Biotechnology) 
• A Phase II prospective randomized trial of dose-escalated radiotherapy with or without short-term androgen deprivation therapy for patients with intermediate risk prostate cancer (RTOG 0815) 
• A Phase III trial of short-term androgen deprivation with pelvic lymph noe or prostate bed only radiotherapy (SPPORT) in prostate cancer patients with a rising PSA after radical prostatectomy (RTOG 0534) 
• A randomized phase III study of maintenance therapy with bevacizumab, pemetrexed or a combination of bevacizumab and pemetrexed following carboplatin, paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (ECOG E5508) 
• A randomized phase III trial of lenalidomine vs. observation alone in patients with asymptomatic high-risk smoldering multiple myeloma (ECOG E3A06)